This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): WT4869
Description: WT4869 is a peptide fragment of WT1, the protein product of the Wilm's tumor gene 1. WT1 is highly expressed in leukemia and some solid tumors. The WT4869 peptide is designed to illicit an immune response against WT1 expressing tumor cells.
Dainippon Sumitomo and Chugai
Based on basic and clinical research results from studies, DSP and Chugai have developed the peptides WT4869 and WT2725 in their collaborative development program.
In April 2013, Dainippon Sumitomo (DSP) and Chugai have agreed to terminate the joint development agreement for WT4869 and WT2725. As a result, future development plans will change. DSP and Chugai have jointly conducted the development of WT4869 and WT2725. However, in order to provide these treatment options to patients as early as possible, the companies concluded that it would be preferable to concentrate development and marketing activities to DSP, and agreed to terminate the joint development agreement. The ongoing Phase I clinical study of WT4869 in Japan will continue to be jointly developed until completion of the studies. Subsequent clinical development for WT4869, and the ongoing development for WT2725 in the U.S. will be solely conducted by DSP. Chugai will receive...See full deal structure in Biomedtracker
Partners: Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: